B Dahlof

Summary

Country: Sweden

Publications

  1. ncbi Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study
    Bjorn Dahlof
    Goteborg University, Sweden
    J Hypertens 23:2063-70. 2005
  2. ncbi Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B
    Bjorn Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Lancet 366:895-906. 2005
  3. ncbi Further evidence for low-dose combinations in patients with left ventricular hypertrophy
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 19:S9-14. 2005
  4. ncbi The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group
    B Dahlof
    Ostra University Hospital, Goteborg, Sweden
    Am J Hypertens 10:705-13. 1997
  5. ncbi Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system
    B Dahlof
    Department of Medicine, University of Goteborg, Ostra Hospital, Sweden
    Am J Hypertens 5:900-11. 1992
  6. ncbi Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
    B Dahlof
    Department of Medicine, University of Goteborg, Ostra Hospital, Goteborg, Sweden
    Am J Hypertens 5:95-110. 1992
  7. ncbi Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    B Dahlof
    Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 18:367-73. 2004
  8. ncbi Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension
    B Dahlof
    Department of Medicine, University of Goteborg, Ostra Hospital, Sweden
    Am J Hypertens 8:578-83. 1995
  9. ncbi Controlled trial of enalapril and hydrochlorothiazide in 200 hypertensive patients
    B Dahlof
    Department of Medicine, Ostra Hospital, University of Gothenburg, Sweden
    Am J Hypertens 1:38-41. 1988
  10. doi Management of cardiovascular risk with RAS inhibitor/CCB combination therapy
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 23:77-85. 2009

Detail Information

Publications13

  1. ncbi Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study
    Bjorn Dahlof
    Goteborg University, Sweden
    J Hypertens 23:2063-70. 2005
    ..The PICXEL study compared the efficacy of a strategy based on first-line combination with perindopril/indapamide versus monotherapy with enalapril in reducing left ventricular hypertrophy (LVH) in hypertensive patients...
  2. ncbi Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B
    Bjorn Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Lancet 366:895-906. 2005
    ..Our aim, therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril...
  3. ncbi Further evidence for low-dose combinations in patients with left ventricular hypertrophy
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 19:S9-14. 2005
    ..This reduction cannot be entirely explained by the better efficacy of the low-dose combination on blood pressure reduction...
  4. ncbi The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group
    B Dahlof
    Ostra University Hospital, Goteborg, Sweden
    Am J Hypertens 10:705-13. 1997
    ..On April 30, 1997, when inclusion was stopped, 9,218 patients had been randomized...
  5. ncbi Reversal of cardiovascular structural changes when treating essential hypertension. The importance of the renin-angiotensin-aldosterone system
    B Dahlof
    Department of Medicine, University of Goteborg, Ostra Hospital, Sweden
    Am J Hypertens 5:900-11. 1992
    ..It can be concluded that the reversal of structural vascular changes during antihypertensive therapy was more dependent on the blockade of the RAAS than on lowering of the blood pressure...
  6. ncbi Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
    B Dahlof
    Department of Medicine, University of Goteborg, Ostra Hospital, Goteborg, Sweden
    Am J Hypertens 5:95-110. 1992
    ..However, this theory and its possible prognostic implications need to be evaluated in controlled prospective trials...
  7. ncbi Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    B Dahlof
    Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 18:367-73. 2004
    ..5-year period. A population-wide prevention strategy of using losartan in patients with LVH and hypertension has the potential to have a major public health impact by reducing the morbidity and mortality of stroke in the EU...
  8. ncbi Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension
    B Dahlof
    Department of Medicine, University of Goteborg, Ostra Hospital, Sweden
    Am J Hypertens 8:578-83. 1995
    ..01). No evidence of rebound hypertension was observed in either group. In conclusion, losartan was as efficacious as atenolol in blood pressure reduction, and was at least as well tolerated...
  9. ncbi Controlled trial of enalapril and hydrochlorothiazide in 200 hypertensive patients
    B Dahlof
    Department of Medicine, Ostra Hospital, University of Gothenburg, Sweden
    Am J Hypertens 1:38-41. 1988
    ..2 mmol/L) in E + H 25. Both regimens were remarkably well tolerated. It can be concluded that H 12.5 mg/day potentiates the effect of Enalapril 25 mg/day at least as well as H 25 mg/day and better than placebo...
  10. doi Management of cardiovascular risk with RAS inhibitor/CCB combination therapy
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Hum Hypertens 23:77-85. 2009
    ..Meanwhile, such a combination offers effective, convenient, well-tolerated control of the most important modifiable risk factor for CVD...
  11. ncbi Introduction
    B Dahlof
    Department of Medicine, Sahlgrenska University Hospital, SE 41685 Gothenburg, Sweden
    Acta Diabetol 42:S1-2. 2005
  12. ncbi Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond
    B Dahlof
    Goteborg University, Goteborg, Sweden
    J Renin Angiotensin Aldosterone Syst 1:S14-6. 2000
    ..This drug may provide additional benefits in controlling the cardiovascular complications of hypertension. Results of large clinical trials with valsartan, such as VALUE, Val-HEFT, VALIANT and ABCD-2V, are eagerly awaited...
  13. ncbi Left ventricular hypertrophy and angiotensin II antagonists
    B Dahlof
    Clinical Experimental Research Laboratory, Sahlgrenska University Hospital, Ostra, Goteborg, Sweden
    Am J Hypertens 14:174-82. 2001
    ..Published data include open-label and randomized studies with losartan treatment for left ventricular hypertrophy, with fewer studies investigating the effects of valsartan, irbesartan, and candesartan...